ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 1191 • ACR Convergence 2020

    Specificity for Inflammatory Pathways Associated with Coronary Microvascular Dysfunction in Rheumatoid Arthritis

    Brittany Weber1, Zeling He1, Sicong Huang1, Daniel H. Solomon2, Elena Massarotti1, Charlotte Golnik1, Thany Seyok1, Seth Brownmiller1, Laurel Martell1, Leann Barrett1, Courtney Bibbo1, Marcy Bolster3, Marcelo DiCarli1 and Katherine Liao1, 1Brigham and Women's Hospital, Boston, MA, 2Brigham & Women's Hospital and Harvard Medical School, Boston, MA, 3Massachusetts General Hospital, Concord, MA

    Background/Purpose: Coronary microvascular disease (CMD) is associated with increased mortality in RA independent of traditional cardiovascular (CV) risk factors. Inflammation likely plays an important role…
  • Abstract Number: 1207 • ACR Convergence 2020

    Impact of Body Mass Index on Clinical Responses of Novel Subcutaneous Infliximab (CT-P13 SC) in Patients with Active Rheumatoid Arthritis: 1-Year Results from a Part 2 of Phase I/III Randomized Controlled Trial

    DaeHyun Yoo1, Rene Westhovens2, Piotr Wiland3, Marek Zawadzki4, Delina Ivanova5, Alfredo Berrocal Kasay6, Elias Chalouhi7, Eva Balázs8, SangJoon Lee9, SungHyun Kim9, NooRi Han9 and YooBin Jung9, 1Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 2University Hospitals Leuven, Belgium, Leuven, Belgium, 3Medical Univeristy, Wroclaw, Poland, 4Medical Univeristy, Dpt of Rheumatology , Wroclaw, Wroclaw, Poland, 5Diagnostic-Consultative Center Aleksandrovska EOOD, Sofia, Bulgaria, 6ABK Reuma SRL, LIMA, Peru, 7Clinica Internacional Sede Lima, Lima, Peru, 8Dr. Bugyi István Hospital, Szentes, Hungary, 9Celltrion, Inc., Incheon, Republic of Korea

    Background/Purpose: In the analysis of PLANETRA, a Phase III randomized controlled trial (RCT), no significant association was found between body mass index (BMI) and clinical…
  • Abstract Number: 1224 • ACR Convergence 2020

    Glucocorticoid Reduction in Different Profiles of Patients with Rheumatoid Arthritis and Treatment with Sarilumab

    Esteban Rubio Romero1, Alejandro Muñoz Jiménez2, Rosalia Martinez Perez3 and Lara Mendez Diaz4, 1VIRGEN DEL ROCIO UNIVERSITY HOSPITAL, SEVILLE, Spain, 2H. U. Virgen del Rocío (Sevilla), Sevilla, Spain, 3Virgen del Rocío University Hospital, seville, Spain, 4Virgen del Rocío Hospital, sevilla, Spain

    Background/Purpose: Glucocorticoid reduction in different profiles of patients with rheumatoid arthritis and sarilumab treatment. Real clinical practice studies are tasked with providing clinically relevant data…
  • Abstract Number: 1245 • ACR Convergence 2020

    Smoking Might Reduce Odds of Sjӧgren’s Syndrome Among Rheumatoid Arthritis Patients

    Sara McCoy1 and Christie Bartels2, 1University of Wisconsin, Madison, 2University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI

    Background/Purpose: Smoking increases the risk of many rheumatic disease, including rheumatoid arthritis (RA). Previous studies have identified that current smoking might reduce the risk of…
  • Abstract Number: 1466 • ACR Convergence 2020

    Multimorbidity in Rheumatoid Arthritis, Psoriatic Arthritis, Gout, and Osteoarthritis Within the Rheumatology Informatics System for Effectiveness (RISE) Registry

    Bryant England1, Huifeng Yun2, Lang Chen3, Kaleb Michaud1, Ted Mikuls1 and Jeffrey R Curtis2, 1University of Nebraska Medical Center, Omaha, NE, 2Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Rheumatic and musculoskeletal diseases (RMDs) often predispose the development of other chronic conditions, resulting in multimorbidity. While multimorbidity is increasingly being recognized and examined…
  • Abstract Number: 1548 • ACR Convergence 2020

    Blood Pressure, BMI and Sex Affect Optical Spectral Transmission Imaging Measurements of the Hands

    Annelies Blanken1, Conny van der Laken2 and Mike Nurmohamed3, 1Amsterdam Rheumatology and immunology Center location Reade, Amsterdam, Netherlands, 2Amsterdam Rheumatology and immunology Center, location Amsterdam UMC, VU medical center, Amsterdam, Netherlands, 3Amsterdam Rheumatology and immunology Center, location Reade and Amsterdam UMC, VU medical center, Amsterdam, Netherlands

    Background/Purpose: Optical spectral transmission imaging (OST) is a new imaging method designed to measure inflammation in the hands of rheumatoid arthritis (RA) patients. The device…
  • Abstract Number: 1696 • ACR Convergence 2020

    Measuring Quality Improvement from CME Participants: Results from the RAPID® CME Initiative

    Stephen Bender1, Michael Weinblatt2 and Daniel Duch1, 1FACTORx, Cherry Hill, NJ, 2Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Medical claims data have been used since 2008 to measure the implementation of the diagnostic and referral strategies resulting from participation in RAPID® CME…
  • Abstract Number: 1726 • ACR Convergence 2020

    Assessment of the Components of RAPID3 Patient Reported Outcomes in an Community Rheumatology Practice

    Elston He1, Pratyusha Yalamanchi2, William Arnold3 and Erin Arnold4, 1Synovium, Inc., Philadelphia, PA, 2Michigan Medicine, Ann Arbor, MI, 3Retired, Wilmette, IL, 4Private Practice, Orthopaedics and Rheumatology of the North Shore, Wilmette, IL

    Background/Purpose: Patient reported outcomes are integral to measuring patient response to treatment for rheumatoid arthritis (RA). RAPID3 is a patient reported outcome metric that consists…
  • Abstract Number: 1743 • ACR Convergence 2020

    Perioperative Steroids in Rheumatoid Arthritis Patients Having Total Joint Replacements: Help or Harm?

    Tariq Chukir1, Susan Goodman2, Haley Tornberg3, Huong Do4, Charlene Thomas5, Alana Sigmund3, Peter Sculco6, Bella Mehta6, Linda Russell6, Mark Figgie2 and Emily Stein7, 1Weill Cornell Medicine and New York Presbyterian Hospital, New York, 2Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 3Hospital for Special Surgery, New York, 4Hospital for Special Surgery, New York, NY, 5Weill Cornell Medicine, New York, 6Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 7Endocrine Service, Hospital for special surgery, Department of Medicine, Weill Cornell Medical College, New York, NY

    Background/Purpose: Optimal perioperative glucocorticoids (GC) dosing for rheumatoid arthritis (RA) patients on chronic GCs undergoing total joint replacement is unknown.  Ideal GC dosing prevents perioperative…
  • Abstract Number: 1760 • ACR Convergence 2020

    The Association Between the Risk of Venous Thromboembolism and Disease Activity in Patients with Rheumatoid Arthritis: A Retrospective Observational Study

    Masaru Yoshimura1, Yuichiro Fujieda2, Michihito Kono2, Masaru Kato2, Kenji Oku2, Olga Amengual2 and Tatsuya Atsumi3, 1Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, 2Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, 3Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapparo, Hokkaido, Japan

    Background/Purpose: Rheumatoid arthritis (RA) is an immune-mediated synovial disease with chronic inflammation. Systemic inflammation is considered one of risk factors for venous thromboembolism (VTE), which…
  • Abstract Number: 1964 • ACR Convergence 2020

    Engaging Patients in the Development of a Quality Measure of Functional Status to Improve Care Among Patients with Rheumatoid Arthritis

    Sarah Hopkins Gillespie1, Liana Fraenkel2, Lisa Suter3, Gabriela Schmajuk4, Patricia Katz5, Alex Limanni6 and Alexis Ogdie1, 1University of Pennsylvania, Philadelphia, PA, 2Yale School of Medicine; West Haven VA; Berkshire Medical Center, Lenox, MA, 3Yale School of Medicine, New Haven, CT, 4University of California, San Francisco, Atherton, CA, 5University of California, San Francisco, Novato, CA, 6n/a, Dallas, TX

    Background/Purpose: The ACR Quality of Care committee is working to develop a quality measure to reflect functional assessment in rheumatoid arthritis (RA). One proposed approach…
  • Abstract Number: 2003 • ACR Convergence 2020

    Individualized Prediction of Response to Methotrexate Treatment in Patients with Rheumatoid Arthritis: A Pharmacogenomics-driven Machine Learning Approach

    Elena Myasoedova1, Arjun Athreya1, Cynthia Crowson2, Richard Weinshilboum1, Liewei Wang1 and Eric Matteson3, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, 3Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester, MN

    Background/Purpose: Methotrexate (MTX) is the most common anchor drug for rheumatoid arthritis (RA), but the risk of missing the opportunity for early effective treatment with alternative medications…
  • Abstract Number: L11 • 2019 ACR/ARP Annual Meeting

    Maintenance of Remission Following Dose De-Escalation of Abatacept in Early, MTX-Naïve, ACPA-Positive Patients with RA: Results from a Randomized Phase IIIb Study

    Paul Emery1, Yoshiya Tanaka 2, Vivian Bykerk 3, Thomas W.J. Huizinga 4, Gustavo Citera 5, Clifton Bingham 6, Subhashis Banerjee 7, Benjamin Soule 8, Marleen Nys 9, Sean Connolly 10, Robert Wong 10, Kuan-Hsiang Gary Huang 7 and Roy Fleischmann 11, 1University of Leeds and Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, 2University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 3Hospital for Special Surgery, New York City, 4Leiden University Medical Center, Leiden, Netherlands, 5Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 6Johns Hopkins University, Baltimore, 7Bristol-Myers Squibb, Princeton, NJ, 8Bristol-Myers Squibb, Princeton, New Jersey, 9Bristol-Myers Squibb, Braine L'Alleud, Belgium, 10Bristol-Myers Squibb, Princeton, 11Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Although EULAR/ACR guidelines suggest tapering biologics following sustained remission in patients (pts) with RA, specific de-escalation (DE) regimens are not fully defined. The Phase…
  • Abstract Number: 500 • 2019 ACR/ARP Annual Meeting

    The Dysregulation of NK Cells and Non-Conventional NK-T and γδ-T Cells in Individuals at Risk of Developing Rheumatoid Arthritis

    Klára Prajzlerová1, Olga Kryštůfková 2, Petra Hánová 3, Hana Hulejová 3, Monika Gregová 1, Nora Petrovská 1, Herman Mann 4, Karel Pavelka 4, Jiří Vencovský 4, Ladislav Senolt 4 and Mária Filková 1, 1Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 2Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague, Czech Republic, 3Institute of Rheumatology, Prague, Czech Republic, 4Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic

    Background/Purpose: The positivity of antibodies against citrullinated proteins (ACPA) precedes the clinical manifestation and significantly increases the risk of rheumatoid arthritis (RA). EULAR characterised individuals…
  • Abstract Number: 538 • 2019 ACR/ARP Annual Meeting

    Long-Term Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to CsDMARDs: Results at 60 Weeks

    Gerd Burmester1, Filip Van den Bosch 2, Louis Bessette 3, Alan Kivitz 4, Yihan Li 5, Alan Friedman 6, Aileen Pangan 6, Heidi Camp 5 and Joel Kremer 7, 1Charité—University Medicine Berlin, Berlin, Germany, 2Ghent University Hospital, Ghent, Belgium, 3Laval University, Quebec City, QC, Canada, 4Altoona Center for Clinical Research, Duncansville, PA, 5AbbVie Inc., North Chicago, IL, 6AbbVie Inc., North Chicago, 7Albany Medical College, Albany, NY

    Background/Purpose: Upadacitinib (UPA), an oral, JAK1-selective inhibitor showed efficacy over 12 weeks (wks) in patients (pts) with moderately to severely active rheumatoid arthritis (RA) and…
  • « Previous Page
  • 1
  • …
  • 161
  • 162
  • 163
  • 164
  • 165
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology